NOV 09, 2017 9:00 AM PST

Accelerating Immuno-Oncology Research with the PanCancer IO 360™ Gene Expression Panel, Advanced Data Analysis Service, and Signature Development

Sponsored by: NanoString Technologies
Speakers
  • Senior Director of Advanced Applications, NanoString Technologies
    Biography
      Sarah Warren is the Senior Director of Translational Science at NanoString Technologies where she leverages multiplexed, molecular profiling technologies to address key research areas in oncology, immunology, and beyond. Her role enables her to work with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. She is also active in the immuno-oncology research community to promote the science and application of cancer immunotherapy to improve patient outcomes. Prior to joining NanoString, she was a founder and director of research at Oncofactor Corp., a biotech startup focused on developing therapeutics which targeted novel immune checkpoints. She has a PhD in immunology from the University of Washington and performed her graduate work at the Institute for Systems Biology.
    • Principal Biostatistician, NanoString
      Biography
        Patrick Danaher leads the biostatistics team at NanoString Technologies. Prior to joining NanoString, he earned his Ph.D. at the University of Washington Department of Biostatistics, working with Pei Wang on analysis methods for high-throughput genomics data. He began his career in gene expression at XDx, one of the first gene expression diagnostics companies.

      Abstract

      Transcriptional profiling of the tumor microenvironment can lead to insights about the interaction between the tumor and immune system. This facilitates investigation of immune evasion mechanisms, enables potential development of novel therapeutics, and allows for possible identification of responder/non-responder populations in immunotherapy research. The NanoString PanCancer IO 360™ Panel is a 770 target, multiplexed gene expression panel developed for characterization of expression patterns from the tumor, immune system, and stroma. It contains the Tumor Inflammation Signature1, which includes 18 functional genes known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade. The IO 360 panel also contains gene content to profile other mechanisms of immune evasion as well as biology relevant to tumor growth and persistence. Furthermore, NanoString has developed additional signatures that describe particular aspects of biology relevant to tumor-immune evasion, including signatures to detect 14 different immune cell populations and 15 additional biological activities such as antigen presentation, mismatch repair deficiency, cytotoxicity, interferon activity, angiogenesis, and stromal abundance. Capturing biological activity with gene signatures can reduce complexity of data analysis and lead to improved sensitivity to detect differences between samples. The signatures being offered with the IO 360 panel are part of a new data analysis service to facilitate research and enable greater characterization of mechanisms of immune evasion.


      Show Resources
      Show Resources
      Attendees